Key result
Certain statins were significantly associated with a reduction in blood pressure, whereas the association between rosuvastatin and hypotension was nonsignificant (adjusted p=0.65).
Why the study?
Do statins increase the risk of hypotension adverse events in patients reported to the FDA Adverse Event Reporting System?
Meta-Analysis (n=5,900,000)
Do statins increase the risk of hypotension adverse events in patients reported to the FDA Adverse Event Reporting System?
p-value: p=0.65
A large-scale analysis of FDA adverse event reports suggests that certain statins are associated with a blood pressure-lowering effect, though this was not observed with rosuvastatin.
Supports hypothesis-generating BP-lowering signals for select statins in FAERS data; leaves open prospective confirmation and clinical hypotension relevance.
OBJECTIVE: As a class of cholesterol-lowering drugs, statins have been reported to cause unexpected decrease in blood pressure (BP). However, most studies in this issue were subject to inadequate study design or very small sample size. The present study was designed to examine the BP-lowering effect of various statins. METHODS: Here we retrieved 5.9 million clinical reports submitted to FDA Adverse Event Reporting System (FAERS) from 2004 to 2015. Meta-analysis was performed to estimate the overall reporting odds ratio (ROR) of hypotension adverse events concurrent with various statins (i.e., atorvastatin, simvastatin, and rosuvastatin). RESULTS: ) were significantly associated with reduction in BP. On the other hand, the association between rosuvastatin and hypotension was observed to be nonsignificant (adjusted p-value = 0.65). CONCLUSION: To our knowledge, this is the first pooled analysis on large-scale data of adverse events to identify the BP-lowering effect of statins. The results will contribute to the development of novel statin-based antihypertensive therapies. In addition, the differential effects of individual statins can warrant subsequent research on the underlying mechanisms of BP control.
No takes yet. Share an insight, caveat, or question.
You et al. (2017) conducted a meta-analysis in Hypotension (n=5,900,000). Statins (atorvastatin, simvastatin, rosuvastatin) was evaluated on Hypotension adverse events (p=0.65). Certain statins were significantly associated with a reduction in blood pressure, whereas the association between rosuvastatin and hypotension was nonsignificant (adjusted p=0.65).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: